

Cytosorbents Corp  
Form 8-K  
April 11, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 11, 2017

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**                                      **001-36792**                                      **98-0373793**  
(State or other jurisdiction of incorporation)    (Commission File Number)    (I.R.S. Employer Identification No.)

**7 Deer Park Drive, Suite K,**

**Monmouth Junction, New Jersey**              **08852**  
(Address of principal executive offices)    (Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

**Not Applicable**

Edgar Filing: Cytosorbents Corp - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 11, 2017, CytoSorbents Corporation, a Delaware corporation (the “Company”), closed the sale of an additional 333,333 shares of the Company’s common stock, pursuant to the underwriters’ full exercise of the over-allotment option. The 30-day option was granted in connection with the Company’s follow-on offering of 2,222,222 shares of common stock which closed on April 5, 2017. The Company received gross proceeds of approximately \$1,500,000 as a result of the exercise of the option, based on a public offering price of \$4.50 per share.

**Item 9.01**

**Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No. Description.**

- |      |  |
|------|--|
| 5.1  | Opinion of DLA Piper LLP (US).                           |
| 23.1 | Consent of DLA Piper LLP (US) (included in Exhibit 5.1). |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 11, 2017 CYTOSORBENTS  
CORPORATION

By: /s/ Dr. Phillip P. Chan  
Name: Dr. Phillip P. Chan  
President and  
Title:  
Chief Executive Officer